With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

As a result, the positive rate of amyloid beta protein, which shows the risk of amyloid accumulation, a causative agent of ...

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...

A groundbreaking study by researchers from the University of Delaware College of Health Sciences and the National Institute ...

Korea University Guro Hospital has opened the Alzheimer's Prevention Center (Center Director Kang Sung-hoon).The Alzheimer's ...

We now find ourselves at a point where commercially available plasma biomarker tests are demonstrating an extremely high ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

Deep sleep could be key to forestalling slow declines in brain health that may one day lead to Alzheimer's disease, the most ...

MRI has shown that increases in the white matter of the brain and ventricle volume may be risk factors for the progression of ...

US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer ...